Document is current
Any future updates will be listed below
-
Authors
Ahmed, Salaheldin https://orcid.org/0000-0001-7086-6262
Ahmed, Abdulla https://orcid.org/0000-0001-6005-5300
Säleby, Joanna https://orcid.org/0000-0003-3581-4154
Bouzina, Habib https://orcid.org/0000-0002-9956-7060
Lundgren, Jakob https://orcid.org/0000-0001-9338-2906
Rådegran, Göran https://orcid.org/0000-0003-4919-2771
-
Funding
Funding for this research was provided by:
ALF
Actelion Pharmaceuticals Sweden AB
- License Information
-
More Information
Article History
Received: 15 October 2019
Accepted: 13 December 2019
First Online: 20 January 2020
Compliance with ethical standards
:
: Mr. Salaheldin Ahmed and Mr. Abdulla Ahmed report no conflicts of interest. Dr. Säleby reports an unrestricted research grant from The Swedish Society of Pulmonary Hypertension on behalf of GlaxoSmithKline. Mr. Bouzina reports an unrestricted research grant from The Swedish Society of Pulmonary Hypertension on behalf of GlaxoSmithKline. Dr. Lundgren reports unrestricted research grants from The Swedish Society of Pulmonary Hypertension on behalf of Actelion Pharmaceuticals Sweden AB. Dr. Rådegran reports unrestricted research grants from ALF and Actelion Pharmaceuticals Sweden AB, during the conduct of the study. Mr. Abdulla Ahmed and Mr. Salaheldin Ahmed report no personal lecture fees. Dr. Säleby reports personal lecture fees from Actelion Pharmaceuticals Sweden AB outside the submitted work. Mr. Bouzina reports personal lecture fees from Actelion Pharmaceuticals Sweden AB outside the submitted work. Dr. Lundgren reports personal lecture fees from Actelion Pharmaceuticals Sweden AB and GlaxoSmithKline outside the submitted work. Dr. Rådegran reports personal lecture fees from Actelion Pharmaceuticals Sweden AB, GlaxoSmithKline, Nordic Infucare and Bayer Health Care outside the submitted work. Dr. Rådegran is, and has been, primary or coinvestigator in clinical PAH trials for GlaxoSmithKline, Actelion Pharmaceuticals Sweden AB, Pfizer, Bayer and United Therapeutics and in clinical heart transplantation immunosuppression trials for Novartis. The companies had no role in the data collection, analysis and interpretation and had no right in disapproving of the manuscript.
